Institutional ownership filings and SEC disclosures for BioXcel Therapeutics (NASDAQ: BTAI) show that equity stakes are distributed among various institutional asset managers and private investment funds, such as Millennium Management, Orakel Capital, and specialized healthcare funds. Individual investment vehicles and institutional holders manage varying share blocks subject to periodic 13F reporting updates filed with regulatory bodies.